News and Trends 11 Oct 2022 Muna Therapeutics gets $4.9M grant for Parkinson’s disease research Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying […] October 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 Neuron23 and QIAGEN to collaborate on diagnostic for novel Parkinson’s drug Neuron23 Inc. and QIAGEN are to collaborate to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease. Under the agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of biomarkers discovered by Neuron23 that together predict the responsiveness of Parkinson’s disease patients to a LRRK2 inhibitor. The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […] September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […] September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Parkinson’s Foundation and Parkinson’s UK partner to drive drug development The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […] June 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jun 2022 Expansion into Europe for BlueRock Therapeutics BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, has established a new site for cell therapy innovation on Bayer’s campus in Berlin, Germany. The move comes as part of the company’s growth strategy. A multidisciplinary BlueRock team will be set up during 2022 to provide clinical development and operational […] June 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Award to help NRG Therapeutics develop new Parkinson’s and Motor Neuron Disease treatments UK neuroscience company NRG Therapeutics Ltd has received a Biomedical Catalyst (BMC) award to fund preclinical development of its small molecule disease-modifying medicines for the treatment of Parkinson’s disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders. The £2.68M ($5.8M) early-stage BMC award part-funded by the government-backed agency Innovate UK will support a […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi AppTec 22 Sep 2021 Discovering New Therapeutic Targets for Alzheimer’s Disease Effective therapies for neurodegenerative diseases like Alzheimer’s are urgently needed. But developing new drugs is difficult, time-consuming, and expensive, with a high risk of failure. Strategic partnerships can help biotech companies manage costs and access the latest technologies to drive innovation and advance novel therapy ideas. A serious unmet medical need Finding treatments for neurodegenerative […] September 22, 2021 - 7 minutesmins - By Julia Kaiser Share WhatsApp Twitter Linkedin Email
News and Trends 12 Aug 2021 European Biotechs Fire up Deals to Develop Parkinson’s Treatments Last month, European biotechs Ipsen and AC Immune announced multi-million euro deals to acquire or license treatments for Parkinson’s disease. For some experts, this increasing interest in the brain disease with the fastest growing prevalence is long overdue. In July, Swiss company AC Immune bought assets and intellectual property for investigational Parkinson’s vaccines valued at […] August 12, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 22 Mar 2021 Can Immunotherapy Offer Hope for Parkinson’s Sufferers? Despite decades of research, effective treatments for Parkinson’s disease are proving elusive. Could immunotherapy finally provide a solution? More than seven million people worldwide are currently living with Parkinson’s disease, an incurable neurodegenerative disorder. Current treatment options are limited as they only attempt to mask the symptoms rather than address the cause. But there is […] March 22, 2021 - 5 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2020 French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable The Bordeaux-based company Treefrog Therapeutics has opened an industrial demonstration plant with the aim of producing cell therapies 10 times more efficiently than with current technology. The €2M plant occupies an area around a fifth of the size of a football field and is expected to produce 80 billion cells per year when it reaches […] June 9, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email